206 filings
Page 5 of 11
8-K
oiepey2yn3v55gthea
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
kcu3q sbq
30 Sep 20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
8:05am
8-K
1zis9o0424xtjag3rpnt
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
424B5
kqlka7d
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
m3jy4czus 35
25 Aug 20
Other Events
7:00am
8-K
rz057pu9
10 Aug 20
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8:06am
8-K
461xmkga
13 Jul 20
Entry into a Material Definitive Agreement
7:06am
8-K
3a282xu0dj5ir
19 Jun 20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
8:06am
8-K
2kla 79o5
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
xyy9rx nc4c
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
mkz5p9 5ceux9b
7 May 20
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
8:10am
DEFA14A
lgwlx4q0fddl2
24 Apr 20
Additional proxy soliciting materials
12:00am
8-K
j0u hkvyatnpgo
30 Mar 20
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
8:05am
8-K
bkivba1v3z4as3g2gq5
13 Mar 20
Regulation FD Disclosure
9:06am
S-8
ug3 3ig38vgt6fx
11 Mar 20
Registration of securities for employees
5:29pm
8-K
4xa51mdexph4n7zqgwbu
11 Mar 20
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
8:05am